Carisma Therapeutics Files 2024 10-K

Ticker: CARM · Form: 10-K · Filed: Mar 31, 2025 · CIK: 1485003

Sentiment: neutral

Topics: 10-K, pharmaceuticals, financials

TL;DR

Carisma Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.

AI Summary

Carisma Therapeutics Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Sesen Bio, Inc., is focused on pharmaceutical preparations. Key financial details and operational highlights for the period are detailed within the filing, which also includes information on subsequent events up to March 31, 2025.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Carisma Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Carisma Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What was Carisma Therapeutics Inc.'s former name?

Carisma Therapeutics Inc. was formerly known as Sesen Bio, Inc., with a name change date of 20180516.

What is the Standard Industrial Classification for Carisma Therapeutics Inc.?

The Standard Industrial Classification for Carisma Therapeutics Inc. is Pharmaceutical Preparations [2834].

What is the business address of Carisma Therapeutics Inc.?

The business address is 3675 Market Street, Suite 401, Philadelphia, PA 19104.

What is the SEC file number for Carisma Therapeutics Inc.?

The SEC file number for Carisma Therapeutics Inc. is 001-36296.

What subsequent events are noted in the filing up to March 31, 2025?

The filing notes subsequent events up to March 31, 2025, including a Cash Preservation Plan for 2025.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 31, 2025 regarding Carisma Therapeutics Inc. (CARM).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing